Preference for a Prefilled Syringe or Smartject Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase IV
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms SMART
- Sponsors Merck Sharp & Dohme
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
- 14 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 23 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.